Aegerion Pharma (AEGR) Misses Q2 EPS by 9c, Sales Beat; Reiterates FY Sales View
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Aegerion Pharmaceuticals Announces Second Quarter 2015 Financial Results
August 5, 2015 4:10 PM EDT- Company records $64.2 million in total net product sales -
- JUXTAPID® net product sales were $57.1 million in the second quarter of 2015, 96% from prescriptions written in the U.S. -
- Company reiterates 2015 total net product sales guidance of between $205 and $235 million -
CAMBRIDGE, Mass., Aug. 5, 2015 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR), a biopharmaceutical company dedicated to the... More
